title: Epstein-Barr virus infection and its gene expression in gastric lymphoma of mucosa-associated lymphoid tissue.
abstract: The role of Epstein-Barr virus (EBV) in the pathogenesis of gastric lymphoma of mucosa-associated lymphoid tissue (MALT) has not been well understood. The aim of the study was to investigate EBV infection and its gene expression in this tumor in order to understand its role in the pathogenesis. EBV infection was screened by in situ hybridization for EBV-encoded non-polyadenylated RNA (EBER ISH) in 79 cases of gastric MALT lymphoma of nonimmunocompromised patients. The expression of EBV proteins [LMP1 (latent membrane protein 1), EBNA2 (EBV nuclear antigen 2), ZEBRA (switch protein encoded by BZLF1 gene)] was studied by immunohistochemistry in EBER-positive cases. EBV was detected with EBER ISH in 15 (19%) of the 79 cases. EBV was found in virtually all tumor cells in 2 cases of high-grade MALT lymphoma (2.5%) (EBV-associated), and was found only in occasional large or small lymphoid cells in 13 cases (16.5%). False positive EBER signal was detected in the mucinous glandular epithelial cells of gastric antrum with FITC-labeled oligonucleotide probe but not with digoxigenin or 35S-labeled riboprobes. Type II latency (EBER+LMP1+ EBNA2-) was detected in both EBV-associated cases. Type III latency (EBER+LMP1+EBNA2+) was also identified in one EBV-associated case besides latency II. Double labeling showed coexpression of LMP1 and EBNA2 in a small number of tumor cells, indicating the presence of type III latency in single cell level. In cases with only occasional EBER-positive large or small lymphoid cells, LMP1 and EBNA2 were not detected. ZEBRA was negative in all the cases. These findings suggest that EBV may contribute to the pathogenesis of a small proportion of high-grade MALT lymphoma, where virtually all tumor cells harbored EBV and the oncogenic viral protein LMP1 was expressed. Moreover, latency III of EBV infection may exist in nonimmunocompromised patient.
authors.affiliation: Department of Pathology, University of Hong Kong, Hong Kong.
authors.forename: W S
authors.initials: WS
authors.lastname: Xu
authors.forename: A C
authors.initials: AC
authors.lastname: Chan
authors.forename: J M
authors.initials: JM
authors.lastname: Lee
authors.forename: R H
authors.initials: RH
authors.lastname: Liang
authors.forename: F C
authors.initials: FC
authors.lastname: Ho
authors.forename: G
authors.initials: G
authors.lastname: Srivastava
mesh_terms: D000818:Animals; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000821:virology*; D019309:Epstein-Barr Virus Nuclear Antigens / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism / Q000472:pathogenicity*; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000821:virology*; D012367:RNA, Viral; D013274:Stomach Neoplasms / Q000473:pathology / Q000821:virology*; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000235:genetics / Q000378:metabolism; D017735:Virus Latency
chemical_list: C037662:EBV-associated membrane antigen, Epstein-Barr virus; D019309:Epstein-Barr Virus Nuclear Antigens; D012367:RNA, Viral; D015534:Trans-Activators; D014763:Viral Matrix Proteins